Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold.
Deficient vascularization is one of the prominent shortcomings of porous tissue-engineering scaffolds, which results in insufficient oxygen and nutrients transportation. Here, heparin cross-linked demineralized bone matrices (HC-DBM) pre-loaded with vascular endothelial growth factor (VEGF) were designed to promote cells and new microvessels invasion into the matrices. After being chemical crosslinked with heparin by N-hydroxysuccinimide and N-(3-di-methylaminopropyl)-N'-ethylcarbodiimide, the scaffold could bind more VEGF than the non-crosslinked one and achieve localized and sustained delivery. The biological activity of VEGF binding on heparinized collagen was demonstrated by promoting endothelial cells proliferation. Evaluation of the angiogenic potential of heparinized DBM loaded with VEGF was further investigated by subcutaneous implantation. Improved angiogenesis of heparinized DBM loaded with VEGF was observed from haematoxylin-eosin staining and immunohistochemistry examination. The results demonstrated that heparin cross-linked DBM binding VEGF could be a useful strategy to stimulate cells and blood vessels invasion into the scaffolds.
Chen
Lei
L
Biotechnology Research Center, Hubei Province Key Laboratory of Natural Products Research and Development, China Three Gorges University, Yichang, People's Republic of China.
He
Zhengquan
Z
Chen
Bing
B
Yang
Maojin
M
Zhao
Yannan
Y
Sun
Wenjie
W
Xiao
Zhifeng
Z
Zhang
Jing
J
Dai
Jianwu
J
D000818:Animals; D018775:Bone Demineralization Technique; D001857:Bone Matrix / Q000737:chemistry* / Q000378:metabolism*; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology; D018786:Bone Substitutes / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D002417:Cattle; D002478:Cells, Cultured; D003432:Cross-Linking Reagents / Q000494:pharmacology; D004526:Efficiency; D048091:Guided Tissue Regeneration / Q000295:instrumentation; D006493:Heparin / Q000737:chemistry*; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D016062:Porosity; D051381:Rats; D017207:Rats, Sprague-Dawley; D054457:Tissue Scaffolds / Q000737:chemistry; D042461:Vascular Endothelial Growth Factor A / Q000493:pharmacokinetics* / Q000494:pharmacology
D018786:Bone Substitutes; D003432:Cross-Linking Reagents; D042461:Vascular Endothelial Growth Factor A; D006493:Heparin